معرفی
Yvan Beaussant, MD, MSc is an Instructor in Medicine at Harvard Medical School and a Principal Investigator at Dana-Farber Cancer Institute. He is affiliated with the Department of Supportive Oncology at DFCI, the Department of Medicine at Harvard Medical School, and the Department of Medicine at Brigham and Women's Hospital. A hematologist and palliative care physician-investigator, his work bridges clinical care and research in psychedelic-assisted therapies for patients with serious illness.
Education
- MD – Medical Doctor
- MSc – Master of Science
Research Interests
Dr. Beaussant's research is centered on the safety and efficacy of psychedelic-assisted therapy in patients with serious illness. His work includes:
- Investigating psilocybin- and MDMA-assisted therapy for depression, adjustment disorder, pain, and existential distress in cancer and other serious illnesses.
- Defining standards of care for psychedelic-assisted therapy across diverse patient populations.
- Conducting qualitative studies with international experts to shape the research agenda in psychedelic palliative care.
His team is actively involved in clinical trials and translational research aimed at integrating psychedelic therapies into palliative care settings.
Research Trends
Dr. Beaussant's recent publications reflect a strong focus on existential distress in cancer patients, group-based psychedelic therapy, and clinical implementation of psychedelic treatments in palliative care. His work spans systematic reviews, qualitative analyses, and case studies, emphasizing both the therapeutic potential and the ethical, practical challenges of psychedelic use in serious illness.
Clinical and Educational Roles
As a practicing hematologist and palliative care physician, Dr. Beaussant integrates clinical insights into his research. He has led seminars at the Harvard Radcliffe Institute and contributes to education on psychedelic-assisted therapy for palliative care providers.
Labs and Teams
Dr. Beaussant leads a multidisciplinary research team at Dana-Farber Cancer Institute focused on psychedelic-assisted therapy in serious illness. His group collaborates with experts in psychiatry, oncology, and palliative care to advance clinical trials and qualitative research in this emerging field.